GlassScriptPhysician profile
Michelle F Midkiff
NPI 1336170927
$1,469.77
in general payments reported to CMS, 2019-2025
25 companies · $46.92 in 2025
The $46.92 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $211 · 2023: $614 · 2024: $598 · 2025: $46.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.52 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $155.60 | 2023-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $130.18 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $119.61 | 2023-2024 | Farxiga, Tezspire, Lokelma |
| Amgen INC. | $114.52 | 2023-2024 | Prolia, Evenity, Repatha |
| Genzyme Corporation | $97.88 | 2023-2024 | |
| Abbott Laboratories | $86.76 | 2023-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $74.01 | 2024 | Ilet Bionic Pancreas |
| Insulet Corporation | $68.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.87 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $62.78 | 2022-2023 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $46.60 | 2022-2023 | |
| Corcept Therapeutics | $45.32 | 2024 | Korlym |
| Regeneron Healthcare Solutions, INC. | $24.89 | 2023 | Dupixent |
| Genentech USA, INC. | $23.23 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.81 | 2024 | Jynarque |
| E.R. Squibb & Sons, L.L.C. | $20.31 | 2024 | Eliquis |
| Mannkind Corporation | $18.94 | 2024 | |
| Pfizer INC. | $18.55 | 2023 | |
| Esperion Therapeutics, INC. | $18.21 | 2023 | Nexletol |
| Ascensia Diabetes Care US INC. | $15.86 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.24 | 2023 | Quviviq |
| Dexcom, INC. | $15.12 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $13.49 | 2023 | Steglatro |
| Amneal Pharmaceuticals LLC | $13.06 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Midkiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.